BioSpace News Archive

Outlook Therapeutics, Inc. today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.

Ocuphire Pharma, Inc. today announced that it has completed enrollment in MIRA-3, the second Phase 3 FDA registration trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM).

Werewolf Therapeutics, Inc. announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.

JUVÉDERM® VOLBELLA® XC, PART OF THE NUMBER ONE CHOSEN COLLECTION OF FILLERS, IS THE FIRST AND ONLY DERMAL FILLER TO RECEIVE FDA APPROVAL FOR THE IMPROVEMENT OF INFRAORBITAL HOLLOWS.

CereVasc, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt System in patients with normal pressure hydrocephalus (NPH).

Cellphire Therapeutics, Inc. announced today the appointment of Pamela B. Conley , Ph.D. to the company’s Board of Directors.

Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process.

Immunome, Inc. (Nasdaq: IMNM), today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University1).

Oncology Pharma Inc. is pleased to announce that the co-development agreement and ongoing work to advance the licensed technology with Nanosmart has identified that the formulations demonstrate the time-release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulation(s).

Biotricity, Inc. announced that it will release its financial results for the third quarter of fiscal 2022, ended December 31, 2021, on Monday, February 14, 2022.